Website profile

Biopharma Apac

Stay informed on the latest biopharmaceutical news, trends, and developments in Asia Pacific with BioPharma APAC. BioPharma Asia ( APAC ) provides in-depth analysis, insights, and expert commentary on drug development, regulatory updates, and industry partnerships in the region.

  • 58articles · 30d
  • 2+ day agolatest article
  • Aug 15, 2026earliest in window
  • 97%with images
  • 216avg words
articles per day
Categories
  • Medical 43
  • Health & Wellness 35
  • Economy, Business & Finance 22
  • Health 20
  • Business & Industrial 18
  • Science & Technology 16
  • Science & Nature 7
  • Finance & Business 6

Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

BioPharma APAC
biopharmaapac.com > news > 81 > 8357 > haemalogix-doses-first-patient-with-kmcar-t-cell-therapy-in-phase-1-multiple-myeloma-trial.html

HaemaLogiX Doses First Patient with KMCAR T-Cell Therapy in Phase 1 Multiple Myeloma Trial

1+ week, 5+ day ago   (207+ words) 27 August 2026 | Thursday | News HaemaLogiX Ltd is pleased to announce another milestone in its ongoing Phase 1 KOALA trial, with the first patient having been safely treated with KMCAR™ T-cell therapy. Following an initial infusion, the patient demonstrated that the treatment was…...

BioPharma APAC
biopharmaapac.com > news > 123 > 8375 > data4life-monash-health-partner-to-accelerate-clinical-trials-and-real-world-evidence-generation.html

Data4Life, Monash Health Partner to Accelerate Clinical Trials and Real-World Evidence Generation

1+ week, 5+ day ago   (180+ words) 01 September 2026 | Tuesday | News Data4Life and Monash Health have partnered to optimize clinical trial design and execution, complemented by educational workshops and professional training programs, with a shared commitment to improving patient outcomes. The Global Relations Office is a new site launched…...

BioPharma APAC
biopharmaapac.com > news > 18 > 8370 > dualitybio-genentech-ink-1b-plus-deal-to-develop-next-generation-adcs-against-drug-resistant-tumours.html

DualityBio, Genentech Ink $1B-Plus Deal to Develop Next-Generation ADCs Against Drug-Resistant Tumours

1+ week, 6+ day ago   (234+ words) 31 August 2026 | Monday | News DUALITYBIO Inc. announced that it has entered into a collaboration and license agreement with Genentech, a member of the Roche Group, to develop next-generation antibody-drug conjugates ("ADCs") built on the Company's proprietary DualityBio Unique Payload Antibody Conjugate…...

BioPharma APAC
biopharmaapac.com > news > 29 > 8349 > taiwans-anbogen-partners-university-of-tokyo-to-advance-abt-301-across-solid-tumours.html

Taiwan’s Anbogen Partners University of Tokyo to Advance ABT-301 Across Solid Tumours

2+ week, 6+ day ago   (742+ words) BioPharma APAC - Taiwan’s Anbogen Partners University of Tokyo to Advance ABT-301 Across Solid Tumours 24 August 2026 | Monday | News Anbogen Therapeutics Inc. (TPEx: 7784) ("Anbogen" or the "Company"), a clinical-stage precision oncology company, announced that it has entered into a Collaborative Research Agreement…...

BioPharma APAC
biopharmaapac.com > news > 47 > 8341 > us-fda-grants-breakthrough-therapy-and-fast-track-designations-to-norroys-68ga-nym096-for-kidney-cancer-imaging.html

US FDA Grants Breakthrough Therapy and Fast Track Designations to NORROY’s 68Ga-NYM096 for Kidney Cancer Imaging

3+ week, 2+ day ago   (142+ words) 21 August 2026 | Friday | News 68Ga-NYM096 is the first China-originated innovative radiopharmaceutical to receive FDA Breakthrough Therapy Designation. It is being developed as a non-invasive PET imaging agent to enable the characterization of indeterminate renal masses identified by Computed Tomography (CT) or Magnetic…...

BioPharma APAC
biopharmaapac.com > news > 97 > 8339 > pillar-biosciences-lc-scrum-asia-and-lsi-medience-partner-on-large-scale-lung-cancer-genomic-screening-in-japan.html

Pillar Biosciences, LC-SCRUM-Asia and LSI Medience Partner on Large-Scale Lung Cancer Genomic Screening in Japan

3+ week, 2+ day ago   (265+ words) 21 August 2026 | Friday | News Pillar Biosciences, Inc. ("Pillar"), LC-SCRUM-Asia and LSI Medience Corporation ("LSI Medience") announced a collaboration to support genomic screening of blood-based samples from patients with lung cancer as part of the LC-SCRUM-Asia project in Japan. Following approval of…...

BioPharma APAC
biopharmaapac.com > news > 120 > 8326 > abelzeta-secures-us-fda-ind-clearance-for-bispecific-car-t-therapy-c-car039-in-large-b-cell-lymphoma.html

AbelZeta Secures US FDA IND Clearance for Bispecific CAR-T Therapy C-CAR039 in Large B-cell Lymphoma

3+ week, 5+ day ago   (58+ words) 18 August 2026 | Tuesday | News The registrational Phase II clinical trial of C-CAR039 for r/r LBCL in CAR-T therapy naïve patients in China is still ongoing. Two Chairs, 11,000 Kilometres Apart: The Human Cost of Asia’s Plasma Dependence China Plus One: Slogan, Strategy,…...

BioPharma APAC
biopharmaapac.com > news > 89 > 8319 > thermo-fisher-scientific-and-kyan-technologies-sign-mou-to-advance-functional-precision-oncology-for-solid-tumours.html

Thermo Fisher Scientific and KYAN Technologies Sign MoU to Advance Functional Precision Oncology for Solid Tumours

4+ week, 11+ hour ago   (177+ words) 14 August 2026 | Friday | News Thermo Fisher Scientific and KYAN Technologies have signed a Memorandum of Understanding (MoU) to collaborate on advancing functional precision oncology approaches for solid tumours. Bringing these capabilities together could provide a more comprehensive view of individual tumour…...